FTC Releases Second Interim Staff Report on Prescription Drug …
2 days ago · The FTC’s latest interim staff report is part of the Commission’s ongoing study of the PBM industry. This report highlights several key insights gained from data and documents obtained from special orders the FTC issued in 2022 under Section 6(b) of the FTC Act, as well as from publicly available information:
FTC Releases Interim Staff Report on Prescription Drug Middlemen
The Federal Trade Commission today published an interim report on the prescription drug middleman industry that underscores the impact pharmacy benefit managers (PBMs) have on the accessibility and affordability of prescription drugs.
FTC doubles down on PBM criticism in new report
1 day ago · The FTC's first report drew a strong response from the PBM sector, with lawsuits filed in both directions. The FTC has accused the big three of operating a "perverse drug rebate system," while the ...
PBMs made billions marking up specialty drugs by more than …
1 day ago · The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...
Top three insurers reaped $7.3 billion through their drug ... - NBC …
1 day ago · The FTC also said these so-called Big Three health care companies — which it estimates administer 80% of all ... Tuesday’s findings come on the heels of a PBM report the FTC released ...
FTC Report Reveals PBM Practices Impacting Competition and …
1 day ago · The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty generic drugs, resulting in $7.3 billion in excess revenue.The report highlighted that ...
FTC Sues Prescription Drug Middlemen for Artificially Inflating …
Sep 20, 2024 · Today, the Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of ...
FTC sues pharmacy benefit managers for inflating price of insulin : …
Sep 21, 2024 · In a new lawsuit filed Friday, the Federal Trade Commission said it's going after one link in the chain: pharmacy benefit managers (PBMs).
How FTC's Battle With PBMs Could Reshape The Pharmaceutical ... - Forbes
Jul 20, 2024 · Now, PBMs are center stage for the FTC. The Federal Trade Commission has turned its attention to these powerful intermediaries and is, according to the Wall Street Journal, considering a...
FTC slams PBMs for boosting specialty drug prices at the expense …
2 days ago · FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system PBMs are ‘charging enormous markups on dozens of lifesaving drugs,’ an agency official said ...